专利号:US-2022233673-A1 优先权日:2019-06-04 标 题:METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STxB) MONOMERS AND OLIGOMERS, AND USES THEREOF 发明人:BILLET ANNE; SCHMIDT FRÉDÉRIC; JOHANNES LUDGER; SERVENT DENIS; MOURIER GILLES; TARTOUR ÉRIC; KAY MICHAEL; FULCHER JAMES M 权利人:INST CURIE; CENTRE NAT RECH SCIENT; INST NAT SANTE RECH MED; COMMISSARIAT A LENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES CEA; APHP ASSIST PUBLIQUE HOPITAUX DE PARIS; UNIV PARIS; UNIV OF UTAH RESEARCH FOUDATION; UNIV UTAH RES FOUND 摘要:A method of producing a monomer of a Shiga toxin B-subunit (STxB) protein or of a variant thereof by peptide chemical synthesis, as well as to a method of producing a pentamer of the STxB protein or of the variant thereof. The methods are particularly advantageous as they overcome major issues typically observed in peptide chemical synthesis, including solubility and purity issues.
专利号:US-2014315720-A1 优先权日:2012-10-24 标 题 :Polysaccharide ester microspheres and methods and articles relating thereto 发明人:FALLON DENIS G; GARRETT THOMAS S; KIZER LAWTON E; ZAZZARA KAREN L; COMBS MICHAEL T; JOHNSON RICHARD K; DEHART GARY 权利人:CELANESE ACETATE LLC 摘要:A method for producing a polysaccharide ester microsphere may include forming a polysaccharide ester product from a polysaccharide synthesis, wherein the polysaccharide ester product comprises a polysaccharide ester and a solvent; diluting the polysaccharide ester product, thereby yielding a polysaccharide ester dope; and forming a plurality of polysaccharide ester microspheres from the polysaccharide ester dope. Suitable polysaccharides may include, but are not limited to, starch, cellulose, hemicellulose, algenates, chitosan, and any combination thereof. Esters thereof may be organic esters (e.g., acetate and the like), inorganic esters (e.g., sulfonates and the like), or combinations thereof. Further, the solids conent of the polysaccharide ester dope, in some instances, may be greater than about 16 wt %.
1: Licata SC, Rowlett JK. Self-administration of bretazenil under progressive-ratio schedules: behavioral economic analysis of the role intrinsic efficacy plays in the reinforcing effects of benzodiazepines. Drug Alcohol Depend. 2011 Jan 15;113(2-3):157-64. doi: 10.1016/j.drugalcdep.2010.07.019. Epub 2010 Aug 30. 2: Munro G, Lopez-Garcia JA, Rivera-Arconada I, Erichsen HK, Nielsen EØ, Larsen JS, Ahring PK, Mirza NR. Comparison of the novel subtype-selective GABAA receptor-positive allosteric modulator NS11394 [3'-[5-(1-hydroxy-1-methyl-ethyl)-benzoimidazol-1-yl]-biphenyl-2-carbonitrile] with diazepam, zolpidem, bretazenil, and gaboxadol in rat models of inflammatory and neuropathic pain. J Pharmacol Exp Ther. 2008 Dec;327(3):969-81. doi: 10.1124/jpet.108.144568. Epub 2008 Sep 12. Epub 2005 Dec 8. Epub 2005 Oct 19. 15: Acri JB, Serdikoff SL, Witkin JM, Sannerud CA. Discriminative stimulus effects of the benzodiazepine receptor partial agonist bretazenil in pigeons and in rats. Behav Pharmacol. 1996 Jan;7(1):72-77.
合成参考文献
参考文献:10.1016/j.bmcl.2012.11.066 摘要:Jackson A, Guilbert BB, Plant SD, Goggi J, Battle MR, Woodcraft JL, Gaeta A, Jones CL, Bouvet DR, Jones PA, O'Shea DM, Zheng PH, Brown SL, Ewan AL, Trigg W. The development of potential new fluorine-18 labelled radiotracers for imaging the GABA(A) receptor. Bioorg Med Chem Lett. 2013 Feb 01;23(3):821–6. doi: 10.1016/j.bmcl.2012.11.066. 参考文献:10.2165/00003088-199223030-00003 摘要:Mandema JW, Danhof M. Electroencephalogram effect measures and relationships between pharmacokinetics and pharmacodynamics of centrally acting drugs. Clin Pharmacokinet. 1992 Sep;23(3):191–215. doi: 10.2165/00003088-199223030-00003. 参考文献:10.1007/pl00005485 摘要:Bizot J, Le Bihan C, Puech AJ, Hamon M, Thiébot M. Serotonin and tolerance to delay of reward in rats. Psychopharmacology (Berl). 1999 Oct;146(4):400–12. doi: 10.1007/pl00005485. 参考文献:10.1007/s00441-006-0284-3 摘要:Möhler H. GABA(A) receptor diversity and pharmacology. Cell Tissue Res. 2006 Nov;326(2):505–16. doi: 10.1007/s00441-006-0284-3.